Nurix Therapeutics, Inc. (NRIX)Healthcare | Biotechnology | Brisbane, United States | NasdaqGM
26.21 USD
-0.67
(-2.474%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 26.64 +0.43 (1.641%) ⇧ (Aug. 28, 2026, 7:53 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:15 a.m. EDT
The long-term investment case is severely compromised by deteriorating fundamentals and a brutal multi-year price trajectory. Despite a massive one-year recovery in 2024, the business has suffered three consecutive years of negative annual returns ending in 2025, with a cumulative loss of over 62% since 2020. This is compounded by shrinking revenues (-79% growth), negative operating margins, and significant cash burn, leaving the company with no sustainable path to profitability. The balance sheet, while currently liquid, cannot offset the structural decline in the business model. In the short term, the outlook remains murky. While the stock has recently rallied off its lows, the momentum is fragile given the lack of positive earnings surprises and the heavy insider selling pressure from executives. The statistical forecast offers no directional edge, and the options market is screaming caution with massive put positioning at lower strikes. Investors should view this as a speculative turnaround play with high risk of permanent capital loss, rather than a value opportunity. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.202073 |
| AutoARIMA | 0.207623 |
| AutoETS | 0.207696 |
| AutoTheta | 0.216194 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 6.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.042 |
| Excess Kurtosis | -1.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 14.441 |
| Revenue per Share | 0.367 |
| Market Cap | 2,720,117,760 |
| Forward P/E | -18.21 |
| Beta | 1.79 |
| Website | https://www.nurixtx.com |
As of Aug. 22, 2026, 1:15 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest at strikes significantly below the current price (14, 16, 17), indicating a strong expectation of further downside. While there is some new call flow near the money, the overwhelming open interest concentration in deep out-of-the-money puts suggests a 'bear put spread' strategy or hedging against a continued decline rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.9500549 |
| Address1 | 1,600 Sierra Point Parkway |
| All Time High | 52.38 |
| All Time Low | 4.22 |
| Ask | 31.75 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Daily Volume10 Day | 1,124,110 |
| Average Daily Volume3 Month | 2,019,625 |
| Average Volume | 2,019,625 |
| Average Volume10Days | 1,124,110 |
| Beta | 1.794 |
| Bid | 18.13 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 3.883 |
| City | Brisbane |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.21 |
| Current Ratio | 6.338 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 26.86 |
| Day Low | 26.125 |
| Debt To Equity | 14.441 |
| Display Name | Nurix Therapeutics |
| Earnings Timestamp | 1,783,627,200 |
| Earnings Timestamp End | 1,791,489,600 |
| Earnings Timestamp Start | 1,791,489,600 |
| Ebitda | -353,180,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.611 |
| Enterprise To Revenue | 63.502 |
| Enterprise Value | 2,334,732,032 |
| Eps Current Year | 1.78718 |
| Eps Forward | -1.43899 |
| Eps Trailing Twelve Months | -3.46 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 415 525 4200 |
| Fifty Day Average | 24.0579 |
| Fifty Day Average Change | 2.1520996 |
| Fifty Day Average Change Percent | 0.08945501 |
| Fifty Two Week Change Percent | 195.0055 |
| Fifty Two Week High | 28.23 |
| Fifty Two Week High Change | -2.0200005 |
| Fifty Two Week High Change Percent | -0.0715551 |
| Fifty Two Week Low | 8.195 |
| Fifty Two Week Low Change | 18.015 |
| Fifty Two Week Low Change Percent | 2.1982915 |
| Fifty Two Week Range | 8.195 - 28.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,595,597,400,000 |
| Float Shares | 79,648,290 |
| Forward Eps | -1.43899 |
| Forward P E | -18.214163 |
| Free Cashflow | -164,635,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 317 |
| Fullday Change | -0.665001 |
| Fullday Change Percent | -2.47442 |
| Fullday Price | 26.64 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -304,167,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.010779999 |
| Held Percent Institutions | 1.13901 |
| Implied Shares Outstanding | 103,781,683 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-07-24 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,764,460,800 |
| Long Business Summary | Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California. |
| Long Name | Nurix Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,720,117,760 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_206907980 |
| Most Recent Quarter | 1,780,185,600 |
| Net Income To Common | -341,351,008 |
| Next Fiscal Year End | 1,795,996,800 |
| Non Diluted Market Cap | 2,789,132,730 |
| Number Of Analyst Opinions | 16 |
| Open | 26.52 |
| Operating Cashflow | -293,704,000 |
| Operating Margins | -10.41734 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 415 660 5320 |
| Post Market Change | 0.4300003 |
| Post Market Change Percent | 1.6405964 |
| Post Market Price | 26.64 |
| Post Market Time | 1,787,961,191 |
| Previous Close | 26.875 |
| Price Eps Current Year | 14.665563 |
| Price Hint | 2 |
| Price To Book | 6.7499356 |
| Price To Sales Trailing12 Months | 73.9846 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.185 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.665001 |
| Regular Market Change Percent | -2.47442 |
| Regular Market Day High | 26.86 |
| Regular Market Day Low | 26.125 |
| Regular Market Day Range | 26.125 - 26.86 |
| Regular Market Open | 26.52 |
| Regular Market Previous Close | 26.875 |
| Regular Market Price | 26.21 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 908,262 |
| Return On Assets | -0.40056 |
| Return On Equity | -0.80296 |
| Revenue Growth | -0.795 |
| Revenue Per Share | 0.367 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 103,781,683 |
| Shares Percent Shares Out | 0.1733 |
| Shares Short | 17,984,342 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 17,979,165 |
| Short Name | Nurix Therapeutics, Inc. |
| Short Percent Of Float | 0.1752 |
| Short Ratio | 17.18 |
| Source Interval | 15 |
| State | CA |
| Symbol | NRIX |
| Target High Price | 45.0 |
| Target Low Price | 25.0 |
| Target Mean Price | 33.5 |
| Target Median Price | 34.0 |
| Total Cash | 443,528,992 |
| Total Cash Per Share | 4.274 |
| Total Debt | 58,143,000 |
| Total Revenue | 36,766,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.46 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 18.50575 |
| Two Hundred Day Average Change | 7.7042484 |
| Two Hundred Day Average Change Percent | 0.41631645 |
| Type Disp | Equity |
| Volume | 908,262 |
| Website | https://www.nurixtx.com |
| Zip | 94,005 |